about
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene.Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasAtherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase.Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional ageA small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistanceA phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemiaPhase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.Advanced glycation end products of DNA: quantification of N2-(1-Carboxyethyl)-2'-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometryA phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agentAroER tri-screen™ is a novel functional assay to estimate both estrogenic and estrogen precursor activity of chemicals or biological specimens.Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins.A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.Low Testosterone Alters the Activity of Mouse Prostate Stem Cells.Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.Iron chelators induce autophagic cell death in multiple myeloma cells.Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6.Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.Tigecycline induction of phenol-soluble modulins by invasive methicillin-resistant Staphylococcus aureus strains.Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.G-to-T transversions and small tandem base deletions are the hallmark of mutations induced by ultraviolet a radiation in mammalian cells.Similar mutagenicity of photoactivated porphyrins and ultraviolet A radiation in mouse embryonic fibroblasts: involvement of oxidative DNA lesions in mutagenesis.Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer.Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
P50
Q33396761-57DA2656-9F7F-4AD1-B8DD-A82F8F8B3AF3Q33895729-1F884C00-80B1-410A-B844-6D0FEE15D73BQ34110178-066B0C0E-59D9-404B-824A-6A54C294DD31Q34231554-43CC2D96-7D2E-4CC4-88CA-55301BB7E2A6Q34349328-6046905E-37D3-476F-9673-B4D597F8D0B8Q34687059-EE931D46-9A27-4B26-BC58-5D558CB2CF81Q34959972-6523A56E-98E5-4C71-916A-6216449801CBQ35000541-E9185C99-9BAE-4359-9ACE-A52A7B0CC36FQ35190641-91FC9DA8-5979-4125-A92B-CD53F0217A18Q35463268-25EDC506-094E-4D82-8040-BAB3354AF625Q35660934-EFAE88E7-A5B8-4EEF-A206-6F8951DBB434Q35782691-017268E3-1205-4DE3-9FFE-F12BFB1DA994Q36090064-FE066FFF-31EB-493F-BB4E-D5AD535D4F0EQ36112971-4C717DDC-9693-4ABE-91B6-B8B07C271C1CQ36852597-75055286-85C4-4917-80F3-7FA8F6609DE9Q36980076-CF6842D8-8240-4CB1-B1C0-ED49A1E5DAA3Q37344283-22A13FA1-CE9D-4826-9A53-842491B0DFE6Q37718554-C848898B-E147-4905-A788-38F407EFF34EQ38282658-B74EEF5B-9032-45BD-A4E9-8CEDBB1D9CF7Q38428175-56685449-EC43-4211-A118-B5E3A1A58625Q38429571-8BF955CD-66A0-4C0A-8C92-CC77D6774FDDQ38439120-C01C7FF6-8F5F-40C2-83DA-01AC9BEEB24EQ38636006-0BD035F6-7028-4BB6-A138-C7904D467B09Q38977723-C67BC497-1989-4423-88A3-1DB2A4F27D60Q39097305-D5441E1C-4578-412E-9187-D342D21D0CB1Q39585359-0811EF6D-3FD0-49CA-A58B-1057B3C0F5B9Q40449697-02DD1271-F305-4774-91CA-EAE2122273C1Q41652561-7018A9C5-3EEC-4D43-95DE-CB3F6E33EA21Q42573064-E3C4B7F4-4643-400C-A208-12F682BCB808Q44561304-799D6413-7FDB-4D99-9FC2-49DC4CD14E90Q44918484-4D42FFB1-A89F-4466-B26C-95268B22CF8BQ44946226-009307EB-1611-44EE-AC91-0C96914295BDQ45174872-4E990D6D-51A7-40E4-B769-52673F740489Q46002146-599DB57C-93E5-46CF-80D5-5A4C5D28E19CQ46086114-0591B59E-C0F6-4853-8577-081861CCF2A2Q46189138-A2E3CF4F-8BB4-4318-AD2D-7BD07C010D2DQ46466258-D95F5F42-FF9E-4331-8D04-F0A2ECE4EAA5Q46521216-7742855C-AD47-42F5-9B10-52B54BD47D3CQ46764721-C7A693E9-4780-43AF-AE8F-8886E2179810Q46979100-EABB7D68-EE52-4AE1-9D98-89A95EC45672
P50
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
Timothy Synold
@en
Timothy Synold
@nl
type
label
Timothy Synold
@en
Timothy Synold
@nl
prefLabel
Timothy Synold
@en
Timothy Synold
@nl
P106
P31
P496
0000-0002-4075-2544